Clinical Research Directory
Browse clinical research sites, groups, and studies.
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
Sponsor: Joshua Woolley, MD, PhD
Summary
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
Official title: Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Key Details
Gender
All
Age Range
40 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2021-08-15
Completion Date
2024-12-31
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
Psilocybin therapy
* Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring * Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring
Locations (1)
University of California, San Francisco
San Francisco, California, United States